Literature DB >> 10919903

Linear IgA bullous disease limited to the eye: a diagnostic dilemma: response to intravenous immunoglobulin therapy.

E Letko1, K Bhol, C S Foster, A R Ahmed.   

Abstract

PURPOSE: To report on a diagnostic dilemma and treatment challenge in a patient with chronic cicatrizing conjunctivitis without involvement of skin and other mucous membranes persisting for 6 years and not responding to topical and systemic steroids.
DESIGN: Interventional case report.
METHODS: We performed direct immunofluorescence of the conjunctiva with fluorescein-conjugated rabbit antihuman antibodies against immunoglobulin A, G, and M, complement 3 component, and fibrinogen. To investigate the presence of circulating antibodies in patient's serum, indirect immunofluorescence using normal human conjunctiva, normal human skin, and monkey esophagus as substrate was done. In addition, we did immunoblot analysis using normal human epidermis as substrate to determine the molecular weight of an antigen. The patient was treated with intravenous immunoglobulin (IVIg). The correlation between the titer of circulating antibodies and the activity of conjunctival inflammation at various intervals during the course of IVIg therapy was demonstrated by immunoblot assay with serial dilutions of the patient's serum. The highest dilution at which the binding was visible was considered the titer.
RESULTS: Direct immunofluorescence of the conjunctiva and indirect immunofluorescence with both salt split skin and conjunctiva as substrate disclosed linear deposition of immunoglobulin A (IgA) at the epithelial basement membrane. Immunoblot analysis demonstrated the presence of IgA circulating antibodies in patient's serum directed against a 97kDa protein in human epidermis. A continuous decrease in the titer of these antibodies correlating to improvement of clinical symptoms was observed during IVIg therapy.
CONCLUSIONS: Use of a nonconventional diagnostic tool (immunoblot analysis), in addition to conventional immunohistologic studies, might be helpful in establishing the diagnosis of patients with chronic cicatrizing conjunctivitis. On the basis of results of these laboratory tests and clinical presentation, we believe that this patient has linear IgA bullous disease limited to the eye. IVIg therapy decreased the titer of circulating antibodies and induced a remission in this patient.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10919903     DOI: 10.1016/s0161-6420(00)00245-1

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  7 in total

1.  High-dose intravenous immunoglobulin (hdIVIg) in the treatment of autoimmune blistering disorders.

Authors:  S Jolles
Journal:  Clin Exp Immunol       Date:  2002-09       Impact factor: 4.330

Review 2.  Autoimmune bullous diseases: ocular manifestations and management.

Authors:  Caroline Laforest; Shyamala C Huilgol; Robert Casson; Dinesh Selva; Igal Leibovitch
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  [Linear IgA disease with ocular involvement associated with ulcerative colitis].

Authors:  A Klein; S M Wenzel; E M Messmer; M Landthaler; T Vogt
Journal:  Hautarzt       Date:  2010-01       Impact factor: 0.751

Review 4.  Evidence for the use of intravenous immunoglobulins--a review of the literature.

Authors:  Shaye Kivity; Uriel Katz; Natalie Daniel; Udi Nussinovitch; Neophytos Papageorgiou; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

5.  Ocular involvement and blindness secondary to linear IgA dermatosis.

Authors:  Cinthya Ramos-Castellón; Gabriela Ortiz-Nieva; Fernando Fresán; Leonardo Villalvazo; Yonathan Garfias; Alejandro Navas; María C Jiménez-Martínez
Journal:  J Ophthalmol       Date:  2010-12-22       Impact factor: 1.909

6.  Shifting Focus in the Therapeutics of Immunobullous Disease.

Authors:  Abhishek De; Asad Ansari; Nidhi Sharma; Aarti Sarda
Journal:  Indian J Dermatol       Date:  2017 May-Jun       Impact factor: 1.494

Review 7.  A review of scoring systems for ocular involvement in chronic cutaneous bullous diseases.

Authors:  Brendon W H Lee; Jeremy C K Tan; Melissa Radjenovic; Minas T Coroneo; Dedee F Murrell
Journal:  Orphanet J Rare Dis       Date:  2018-05-22       Impact factor: 4.123

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.